
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech's financial position is bolstered by a robust liquidity position, ending the third quarter of 2025 with approximately €16.7 billion in cash, cash equivalents, marketable securities, and trade receivables, which provides a strong foundation for continued investment in its extensive oncology pipeline. Positive developments surrounding BNT323, specifically in its Phase 3 DYNASTY-Breast02 trial, suggest potential advancements in targeted cancer therapies that could enhance market competitiveness and revenue streams. Furthermore, the efficacy of its LP.8.1-adapted monovalent COVID-19 vaccine in generating strong immune responses against various SARS-CoV-2 sublineages highlights BioNTech's ongoing relevance in the infectious disease market, complementing its core focus in oncology.
Bears say
BioNTech faces several significant risks that contribute to a negative outlook, including potential negative clinical data across multiple drug candidates, which could hinder the advancement of its oncology pipeline. Additionally, the company reported a net loss per diluted share of €0.12 for the third quarter of 2025, with projections indicating a full-year net loss of €3.99 per diluted share, reflecting ongoing financial challenges. The changing dynamics in the COVID-19 vaccine market, particularly due to stricter regulations in the U.S., may divert investor focus away from BioNTech's core oncology portfolio in the near term.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares